A letter about FDA oncology consolidation reopens debate among cancer groups; FDA asks groups not to send letters, invites discussion.
Also in this 12-page issue: GM Cancer Research Foundation awards annual prizes to four scientists.
Age-adjusted cancer incidence and mortality down slightly, annual report finds.
Bills in House, Senate, would give FDA authority over tobacco products.
Surgeon General’s report adds to list of smoking-related cancers, other diseases.
ASCO honors physicians for clinical trials participation.
President’s Cancer Panel urges comprehensive health care reform, provision of services for cancer survivors.
Funding opportunities listed.
Trending Stories
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns
